David Jayabalan
0000-0002-7938-825X
Publication & Citation Trends
Publications
0 total
Morphologic and immunophenotypic characterization of lymphocytosis following BCMAtargeted CAR-T cell therapy in relapsed/refractory multiple myeloma.
Cited by 0
Semantic Scholar
Anakinra Prophylaxis during BCMA-Directed CAR-T Therapy: A Two-Center Analysis of Toxicity and Outcomes
Cited by 0
Semantic Scholar
CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma
Cited by 0
Semantic Scholar
Systematic Assessment of MYC by Fluorescence in situ Hybridization in Multiple Myeloma Identifies a High-Risk Population Independent of Other Risk Factors
Cited by 0
Semantic Scholar
MYC rearrangements with immunoglobulin genes as an independent prognostic factor of progression-free survival in newly diagnosed patients
Cited by 0
Semantic Scholar
P-053 Early Absolute Lymphocyte Count after BCMA CAR-T as a Surrogate for CAR-T Expansion, Response, and Progression Free Survival in Multiple Myeloma
Cited by 0
Semantic Scholar
CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma
Cited by 0
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(130)
Protein Degradation and Inhibitors
(57)
Cancer Treatment and Pharmacology
(31)
Peptidase Inhibition and Analysis
(22)
Histone Deacetylase Inhibitors Research
(17)
Affiliations
Albert Einstein College of Medicine
NewYork–Presbyterian Hospital
The University of Western Australia
Cornell University
Jacobi Medical Center